Out of Date, Out of Touch - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Out of Date, Out of Touch
Look ahead to keep from falling behind.


Pharmaceutical Technology

Gazinta-heit



"I was the new employee and needed some information," says our GMP Agent-in-Place. "Our company makes 300 products, and some products use common ingredients. We had to make a change in one commonly used ingredient and wanted to be sure that we had evaluated the effects for all the necessary products. Because I was new, I didn't know how to figure this out except by looking at all the formulas, and I voiced this frustration to my boss. She told me to use the 'Gazinta Report.'

"So I asked several people for this report, and was given a six-inch thick computer printout. But when I looked at the title, it didn't say Gazinta, and I thought I had the wrong data. When I asked my boss again, she laughed and told me to read the name fast. Apparently, the original request for what is commonly known as 'where used' data was requested as 'what the ingredient goes into,' and the printout was titled 'Goes Into Report.'"

When good sales are bad news

"Our product is ancient, but it is one of the reasons this factory was built in the 1950s," explains our GMP Agent-in-Place. "The product starts with frozen animal-based ingredients and progresses through several extraction and purification steps, all developed in the 1950s and with 1950s materials.

"As time passed, however, sales declined, and production tailed off. The raw materials that were once sufficient for two or three years now could last 10 years. Even so, we depleted these inventories and had to reorder, especially one key purification media. At the time, the vendor said it hadn't manufactured the media for the past 10 years.

"We searched and tested material from other sources, but the yields from using the alternatives were very low. Our purchasing agent negotiated with the supplier for a one-time manufacturing run of a 'lifetime supply.' The supplier brought an employee out of retirement to provide the needed manufacturing expertise, and made enough to last 10–15 years given our declining sales of the product.

"That was nine years ago.

"Since then, the only competitor for the finished product has left the market, so our sales have increased. Our 15-year supply of media is gone. Once again we called on our supplier, begging them to make more for us. But now the answer was different. The necessary equipment had been scrapped, the retired employee had passed on, and the formulas had been destroyed. And so we are stuck using a lesser yielding alternate media."

Paper-trained

"We had been testing and releasing a liquid parenteral product for years," explains our GMP Agent-in-Place. "The stability testing had always passed until the pH failed when tested on stability, and no one could figure out why. We investigated changes in container, closure, excipients, the raw material, and even our stability storage area and came up with nothing. The quality-control laboratory was asked to check out the performance of the pH method to be sure it was followed correctly. We had left this to last because we had thought no one could screw up a pH test! When the laboratory manager asked the technician how she normally performed the pH test for release of the product, he got the answer: 'I used pH paper like I always have, and compare the color change to the schema on the bottle.'"

Pharmaceutical Technology's monthly "Agent-in-Place" column distills true-life cautionary tales from the secret files of Control, a senior compliance officer. If you have a story of clueless operators, oblivious management, inopportune lapses of judgment, or Murphy's Law in action, please send it to Control at
We won't use any names, but if we do use your tale of disaster, courage, or just plain weirdness, Control will send you a coveted Pharmaceutical Technology t-shirt.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
27%
Breakthrough designations
9%
Protecting the supply chain
41%
Expedited reviews of drug submissions
9%
More stakeholder involvement
14%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here